Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Viridian Therapeutics ( (VRDN) ) just unveiled an update.
On May 5, 2026, Viridian Therapeutics reported positive topline results from its phase 3 REVEAL-2 trial of elegrobart, a subcutaneous anti-IGF-1R antibody, in chronic thyroid eye disease. The study met primary endpoints for both U.S. and European regulators, with proptosis responder rates of 50% and 54% for Q4W and Q8W dosing versus 15% for placebo, alongside significant improvements in diplopia and a generally well-tolerated safety profile with low hearing-impairment rates.
REVEAL-2 is Viridian’s second successful pivotal phase 3 study of elegrobart, following REVEAL-1 in active thyroid eye disease, supporting plans for a Biologics License Application targeted for early 2027. Combined with the anticipated U.S. launch of veligrotug, which has Breakthrough Therapy Designation and a PDUFA action date of June 30, 2026, the data strengthen Viridian’s position in the thyroid eye disease market and suggest operational leverage from shared commercial infrastructure.
The most recent analyst rating on (VRDN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.
Spark’s Take on VRDN Stock
According to Spark, TipRanks’ AI Analyst, VRDN is a Neutral.
The score is primarily weighed down by sustained heavy losses and cash burn (despite a strong, no-debt balance sheet). Technicals also point to a weak downtrend. Offsetting these risks, the positive Phase 3 REVEAL-1 readout is a meaningful catalyst that improves the fundamental outlook.
To see Spark’s full report on VRDN stock, click here.
More about Viridian Therapeutics
Viridian Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for patients with autoimmune and rare diseases. Leveraging its expertise in antibody discovery and protein engineering, the company is advancing multiple late-stage anti-insulin-like growth factor-1 receptor candidates for thyroid eye disease, including veligrotug and elegrobart for active and chronic forms of the condition.
Average Trading Volume: 2,148,895
Technical Sentiment Signal: Sell
Current Market Cap: $1.44B
Find detailed analytics on VRDN stock on TipRanks’ Stock Analysis page.